Lv31
230 积分 2024-06-01 加入
Microbiota therapeutics for inflammatory bowel disease: the way forward
3小时前
待确认
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond
5天前
已完结
Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial
1个月前
已完结
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
1个月前
已完结
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
1个月前
已关闭
LncRNA FAISL Inhibits Calpain 2‐Mediated Proteolysis of FAK to Promote Progression and Metastasis of Triple Negative Breast Cancer
2个月前
已完结
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
2个月前
已完结
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
2个月前
已完结
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer
2个月前
已完结
Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells
2个月前
已完结
皖公网安备34019202002308
